CAMP4 Therapeutics Corporation (CAMP)

In November 2025, CAMP4 announced an inducement grant, reported its Third Quarter 2025 financial results, and filed a follow-on equity offering of up to $100 million. In October 2025, CAMP4 Therapeutics initiated GLP Toxicology Studies for CMP-SYNGAP-01. In September 2025, the company announced an oversubscribed private placement of up to $100 million and reported management changes. In August 2025, CAMP4 reported its Second Quarter 2025 financial results, with Q2 revenue beating estimates. In June 2025, the stock experienced a significant decline and was dropped from the Russell Small Cap Completeness Index and the Russell 2000 Value Index. In May 2025, the company presented translational data from its SYNGAP1-Related Disorders program, reviewed preclinical and safety data from its Urea Cycle Disorders program, reported its First Quarter 2025 financial results, and had its coverage initiated by Wedbush with an Outperform rating.

There is no readily available information indicating demand seasonality for CAMP4 Therapeutics Corp.'s products or services. Its revenue generation is primarily driven by research and development milestones, collaborations, and private placements.

CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing regulatory RNA-based therapeutics to upregulate gene expression for treating genetic diseases, particularly those affecting the central nervous system and liver. Its major product candidates include CMP-CPS-001, currently in Phase 1 clinical trial for urea cycle disorders, and CMP-SYNGAP, in development for SYNGAP1-related disorders with GLP toxicology studies initiated in October 2025. The company operates within the Healthcare sector and the Biotechnology industry.

CAMP4 Therapeutics Corporation is headquartered in Cambridge, Massachusetts, United States, with its primary operational and research activities concentrated in the United States.

CAMP4 Therapeutics' brand reputation has been tied to its scientific progress and financial standing. The company has received a "Strong Buy" consensus rating from analysts, with several initiating coverage with "Overweight" or "Outperform" recommendations. Stock performance fluctuations have not negatively impacted the company's scientific or ethical reputation.

CAMP4 Therapeutics Corporation's ownership is a mix of institutional and individual investors. Institutional investors hold approximately 36.25% to 51.86% of the company's stock. Andrew J. Schwab is the largest individual shareholder, holding 8.49 million shares, representing 18.12% of the company. Key insiders, including Kelly Gold, Yuri Maricich, Joshua Mandel-Brehm, and Richard Young, have recently purchased shares.